IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma
Open Access
- 30 November 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 109 (7), 3060-3068
- https://doi.org/10.1182/blood-2006-07-036368
Abstract
Adult T-cell leukemia/lymphoma (ATLL) is a generally fatal malignancy. Most ATLL patients fare poorly with conventional chemotherapy; however, antiviral therapy with zidovudine (AZT) and interferon alpha (IFN-α) has produced long-term clinical remissions. We studied primary ATLL tumors and identified molecular features linked to sensitivity and resistance to antiviral therapy. Enhanced expression of the proto-oncogene c-Rel was noted in 9 of 27 tumors. Resistant tumors exhibited c-Rel (6 of 10; 60%) more often than did sensitive variants (1 of 9; 11%). This finding was independent of the disease form. Elevated expression of the putative c-Rel target, interferon regulatory factor-4 (IRF-4), was observed in 10 (91%) of 11 nonresponders and in all tested patients with c-Rel+ tumors and occurred in the absence of the HTLV-1 oncoprotein Tax. In contrast, tumors in complete responders did not express c-Rel or IRF-4. Gene rearrangement studies demonstrated the persistence of circulating T-cell clones in long-term survivors maintained on antiviral therapy. The expression of nuclear c-Rel and IRF-4 occurs in the absence of Tax in primary ATLL and is associated with antiviral resistance. These molecular features may help guide treatment. AZT and IFN-α is a suppressive rather than a curative regimen, and patients in clinical remission should remain on maintenance therapy indefinitely.Keywords
This publication has 80 references indexed in Scilit:
- Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescenceBlood, 2006
- Bone marrow transplantation from unrelated donors for patients with adult T-cell leukaemia/lymphomaBone Marrow Transplantation, 2005
- Animal models for human T-lymphotropic virus type 1 (HTLV-1) infection and transformationOncogene, 2005
- Azidothymidine inhibits NF-κB and induces Epstein-Barr virus gene expression in Burkitt lymphomaBlood, 2005
- Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray studyJournal of Cutaneous Pathology, 2005
- Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitroLeukemia, 2004
- Review: The Role of IRF-4 in B and T Cell Activation and DifferentiationJournal of Interferon & Cytokine Research, 2002
- Possible Involvement of Interferon Regulatory Factor 4 (IRF4) in a Clinical Subtype of Adult T-Cell LeukemiaJapanese Journal of Cancer Research, 2001
- Activation and Regulation of Interferon Regulatory Factor 4 in HTLV Type 1-Infected T LymphocytesAIDS Research and Human Retroviruses, 2000
- The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappa B that blocks TNFalpha -induced apoptosisGenes & Development, 1999